利妥昔单抗维持治疗可提高滤泡淋巴瘤无进展生存率  

Follicular Lymphoma Patients Could Benefit from Rituximab Maintenance

作　　者：李文瑜[1] 陈菲莉[1] LI Wen-yu;CHEN Fei-li(Lymphoma Department,Cancer Center,Huifu Branch of Guangdong Provincial People􀆳s Hospital,Guangdong Academy of Medical Sciences,Guangzhou 510080,China;不详)

机构地区：[1]广东省人民医院惠福分院肿瘤中心淋巴瘤科、广东省医学科学院,广州510080

出　　处：《循证医学》2020年第2期83-84,共2页The Journal of Evidence-Based Medicine

摘　　要：1文献来源Bachy E, Seymour J F,Feugier P, et al.Sustained progression-free survival benefit ofRituximab maintenance in patients with follicularlymphoma:Long-term results of the PRIMA study[J].J Clin Oncol,2019,37(31):2815-2824.2证据水平1b。

关 键 词：利妥昔单抗 滤泡淋巴瘤 

分 类 号：R733.4[医药卫生—肿瘤]